AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05086692
Drug: Pembrolizumab (KEYTRUDA®)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
Trial: NCT06653946
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
Trial: NCT05667298
Drug: Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible.
Trial: NCT06468644
Drug: chemoradiotherapy （CRT）+sintilimab 1
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
Trial: NCT06468644
Drug: CRT+sintilimab 2
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
Trial: NCT05953584
Drug: Etavopivat
RxNorm normalized name: Etavopivat
DrugBank: Etavopivat (DB18176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
Trial: NCT05953584
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a stable dose of HU.
Trial: NCT00023816
Drug: carbendazim
RxNorm normalized name: Carbendazim
DrugBank: Carbendazim (DB13009)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06427707
Drug: Intravenous Infusion of propofol, lidocaine, Magnesium sulfate
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. the effect of either Propofol injection, or ketamine injection or dexmeditomidine injection on intraoperative bleeding
Trial: NCT06427707
Drug: Intravenous infusion of ketamine, lidocaine, Magnesium sulfate
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenous infusion of Ketamine 0.1-0.2 mg.kg-1.h-1 (intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. dose of 1 mg.kg-1), lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1.
Trial: NCT06427707
Drug: Intravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexmeditomidine (Precedex® 200 mcg.2ml-1) with a rate of 0.2-0.6 mcg.Kg-1.h-1. lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1
Trial: NCT04827004
Drug: Anlotinib Hydrochloride Capsules
RxNorm normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Trial: NCT05829603
Drug: Dimethyltryptamin (DMT) & Harmine
DrugBank: Harmine (DB07919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
Trial: NCT05147857
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
Trial: NCT04921358
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT04921358
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT04921358
Drug: Sitravatinib
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT03709550
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03709550
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05932199
Drug: Durvalumab / tremelimumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL.
Trial: NCT05932199
Drug: Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL.
Trial: NCT00002335
Drug: Emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04614766
Drug: Lutathera
RxNorm normalized name: Lutathera
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT04614766
Drug: Azedra
RxNorm normalized name: Azedra
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration
Trial: NCT06209112
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
Trial: NCT06583551
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
Trial: NCT04953923
Drug: Cedazuridine
RxNorm normalized name: Cedazuridine
DrugBank: Cedazuridine (DB15694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT04953923
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT05455502
Drug: VX-548
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT06040346
Drug: Meplazumab for Injection
RxNorm normalized name: mepolizumab Injection
DrugBank: Meplazumab (DB16465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
Trial: NCT05403554
Drug: Biological NI-1801
RxNorm normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
Trial: NCT05403554
Drug: NI-1801 in combination with anti-PD1 (Pembrolizumab)
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
Trial: NCT05403554
Drug: NI-1801 in combination with paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
Trial: NCT05403554
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
Trial: NCT06406127
Drug: Alpha Lipoic Acid 600 MG Oral Capsule
RxNorm normalized name: alpha lipoic acid 600 MG Oral Capsule
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 600 mg daily dose
Trial: NCT06109428
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 125 mg
Trial: NCT05449028
Drug: H. pylori eradication scheme D
DrugBank: Heme D (DB03469)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
Trial: NCT04540861
Drug: Siponimod
RxNorm normalized name: SIPONIMOD
DrugBank: Siponimod (DB12371)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
Trial: NCT04814069
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg q3w
Trial: NCT06572215
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
Trial: NCT06587347
Drug: Tirofiban Hydrochloride
RxNorm normalized name: Tirofiban Hydrochloride
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.
Trial: NCT04943016
Drug: CD19 Chimeric Antigen Receptor (CAR) T Cells
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies. The overall goal of this study is to validate the safety profile of administration CD19 CAR T cells and describe the toxicities in children and adults with relapsed/ refractory B cell malignancies. Each patient implements leukapheresis 2 weeks after enrollment and infuse CD19 CAR-T cell around 2 weeks after leukapheresis, and administrated chemotherapy lymphodepletion regimen 1 week before infusion. Furthermore, the treated subject would be following up around 2 years.
Trial: NCT06074016
Drug: Zolmitriptan intranasal.
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
Trial: NCT06074016
Drug: Zolmitriptan oral.
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
Trial: NCT05101187
Drug: Olorofim
RxNorm normalized name: Olorofim
DrugBank: Olorofim (DB15245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
Trial: NCT01142414
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06014255
Drug: Enoblituzumab
RxNorm normalized name: Enoblituzumab
DrugBank: Enoblituzumab (DB15017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
Trial: NCT05448001
Drug: Lansoprazole 30mg
RxNorm normalized name: LANSOPRAZOLE 30MG CAP,SA
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
Trial: NCT00018109
Drug: glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06570967
Drug: Methimazole(MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.
Trial: NCT06541444
Drug: NK520
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.
Trial: NCT05229003
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 8mg or 10mg, d1-9，q2w
Trial: NCT05229003
Drug: Penpulimab
RxNorm normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penpulimab 200mg, d6, q2w
Trial: NCT05229003
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 180mg/m2, d6, q2w
Trial: NCT04730427
Drug: GX-I7
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human interleukin-7 hybrid Fc
Trial: NCT04730427
Drug: GX-I7 vehicle
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation buffer of recombinant human interleukin-7 hybrid Fc
Trial: NCT03160430
Drug: apabetalone
RxNorm normalized name: Apabetalone
DrugBank: Apabetalone (DB12000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVX000222 oral (apabetalone), 100 mg capsule
Trial: NCT06126562
Drug: Lanifibranor
RxNorm normalized name: Lanifibranor
DrugBank: Lanifibranor (DB14801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
Trial: NCT05509816
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT05954429
Drug: serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10
Trial: NCT05954429
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
Trial: NCT04690608
Drug: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
RxNorm normalized name: TRIAMCINOLONE ACETONIDE 40MG/ML INJ,SUSP_#1
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
Trial: NCT05509816
Drug: Imlunestrant
RxNorm normalized name: Imlunestrant
DrugBank: Imlunestrant (DB19043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT02001584
Drug: Baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02001584
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05578378
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.
Trial: NCT05578378
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen
Trial: NCT04800185
Drug: Crisaborole 2% Top Oint
RxNorm normalized name: CRISABOROLE 2% TOP OINT
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
Trial: NCT06573411
Drug: ACEI/ARB+ finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
Trial: NCT05430386
Drug: HS-10241
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy.